

The Mechanistic Basis for Photobiomodulation Therapy of Neuropathic Pain by Near Infrared Laser Light

Vanessa Milanesi Holanda, MD, PhD,^{1,2*} Maria Cristina Chavantes, MD, PhD,^{1,3} Xingjia Wu, BS, and Juanita J. Anders, PhD⁴

¹Post Graduate Program in Biophotonics Applied to the Health Sciences, University Nove de Julho—UNINOVE, São Paulo, SP 01504-001, Brazil

²Center of Neurology and Neurosurgery Associates (CENNA), Beneficência Portuguesa of São Paulo Hospital, São Paulo, SP 01323-030, Brazil

³Post Graduate Program in Medicine, University Nove de Julho—UNINOVE, São Paulo, SP 01504-001, Brazil

⁴Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814

Background and Objective: Various irradiances have been reported to be beneficial for the treatment of neuropathic pain with near infrared light. However, the mechanistic basis for the beneficial outcomes may vary based on the level of irradiance or fluence rate used. Using *in vivo* and *in vitro* experimental models, this study determined the mechanistic basis of photobiomodulation therapy (PBMT) for the treatment of neuropathic pain using a high irradiance.

Study Design/Materials and Methods: *In vitro* experiments: Cultured, rat DRG were randomly assigned to control or laser treatment (LT) groups with different irradiation times (2, 5, 30, 60, or 120 seconds). The laser parameters were: output power = 960 mW, irradiance = 300 mW/cm², 808 nm wavelength, and spot size = 3 cm diameter/area = 7.07 cm², with different fluences according to irradiation times. Mitochondrial metabolic activity was measured with the MTS assay. The DRG neurons were immunostained using a primary antibody to β -Tubulin III. *In vivo* experiments: spared nerve injury surgery (SNI), an animal model of persistent peripheral neuropathic pain, was used. The injured rats were randomly divided into three groups ($n = 5$). (i) Control: SNI without LT; (ii) Short term: SNI with LT on day 7 and euthanized on day 7; (iii) Long term: SNI with LT on day 7 and euthanized on day 22. An 808 nm wavelength laser was used for all treatment groups. Treatment was performed once on day 7 post-surgery. The transcutaneous treatment parameters were: output power: 10 W, fluence rate: 270 mW/cm², treatment time: 120 seconds. The laser probe was moved along the course of the sciatic/sural nerve during the treatment. Within 1 hour of irradiation, behavior tests were performed to assess its immediate effect on sensory allodynia and hyperalgesia caused by SNI.

Results: *In vitro* experiments: Mitochondrial metabolism was significantly lower compared to controls for all LT groups. Varicosities and undulations formed in neurites of DRG neurons with a cell body diameter 30 μ m or less. In neurites of DRG neurons with a cell body diameter of greater than 30 μ m, varicosities formed only in the 120 seconds group. *In vivo* experiments: For heat hyperalgesia,

there was a statistically significant reduction in sensitivity to the heat stimulus compared to the measurements done on day 7 prior to LT. A decrease in the sensitivity to the heat stimulus was found in the LT groups compared to the control group on days 15 and 21. For cold allodynia and mechanical hyperalgesia, a significant decrease in sensitivity to cold and pin prick was found within 1 hour after LT. Sensitivity to these stimuli returned to the control levels after 5 days post-LT. No significant difference was found in mechanical allodynia between control and LT groups for all time points examined.

Conclusion: These *in vitro* and *in vivo* studies indicate that treatment with an irradiance/fluence rate at 270 mW/cm² or higher at the level of the nerve can rapidly block pain transmission. A combination therapy is proposed to treat neuropathic pain with initial high irradiance/fluence rates for fast pain relief, followed by low irradiance/fluence rates for prolonged pain relief by altering chronic inflammation. *Lasers Surg. Med.*

© 2017 Wiley Periodicals, Inc.

Key words: dorsal root ganglion; fluence rate; laser irradiation; photoneuromodulation; transient neuronal injury

INTRODUCTION

Neuropathic pain is a common, debilitating disorder with a complex etiology [1]. Although a number of pharmacologic agents have been used to treat neuropathic

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

Contract grant sponsor: CRADA.

*Correspondence to: Vanessa Milanesi Holanda, Rua Martiano de Carvalho, 807-suite 705, Bela Vista, São Paulo, SP 01321-001, Brazil. E-mail: vanessamila@gmail.com

Accepted 16 December 2016

Published online in Wiley Online Library

(wileyonlinelibrary.com).

DOI 10.1002/lsm.22628